Taysha Gene Therapies, Inc. TSHA
We take great care to ensure that the data presented and summarized in this overview for Taysha Gene Therapies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TSHA
View all-
Rtw Investments, LP New York, NY24.4MShares$103 Million1.03% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$99.2 Million1.27% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$91.4 Million0.93% of portfolio
-
Morgan Stanley New York, NY19.3MShares$81.3 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY13.4MShares$56.3 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$55.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.7MShares$49.4 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY11MShares$46.4 Million1.41% of portfolio
-
Octagon Capital Advisors LP New York, NY9.07MShares$38.2 Million9.31% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.33MShares$30.9 Million0.05% of portfolio
Latest Institutional Activity in TSHA
Top Purchases
Top Sells
About TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Insider Transactions at TSHA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 26
2026
|
Kamran Alam CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
23,849
-1.63%
|
$95,396
$4.61 P/Share
|
|
Jan 26
2026
|
Sean P. Nolan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,312
-1.4%
|
$165,248
$4.61 P/Share
|
|
Jan 26
2026
|
Sukumar Nagendran President and Head of R&D |
SELL
Open market or private sale
|
Direct |
26,918
-2.0%
|
$107,672
$4.61 P/Share
|
|
Jan 23
2026
|
Kamran Alam CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
78,968
-5.11%
|
$315,872
$4.75 P/Share
|
|
Jan 23
2026
|
Sean P. Nolan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
136,789
-4.43%
|
$547,156
$4.75 P/Share
|
|
Jan 23
2026
|
Sukumar Nagendran President and Head of R&D |
SELL
Open market or private sale
|
Direct |
89,132
-6.22%
|
$356,528
$4.75 P/Share
|
|
Jan 12
2026
|
Sukumar Nagendran President and Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
427,000
+22.95%
|
-
|
|
Jan 12
2026
|
Sukumar Nagendran President and Head of R&D |
SELL
Open market or private sale
|
Direct |
200,000
-16.58%
|
$800,000
$4.71 P/Share
|
|
Jan 12
2026
|
Sukumar Nagendran President and Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+7.95%
|
$200,000
$1.21 P/Share
|
|
Jan 12
2026
|
Sean P. Nolan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,008,000
+24.62%
|
-
|
|
Jan 12
2026
|
Kamran Alam CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
359,000
+18.84%
|
-
|
|
Dec 01
2025
|
Sukumar Nagendran President and Head of R&D |
SELL
Open market or private sale
|
Direct |
260,047
-20.53%
|
$1,040,188
$4.51 P/Share
|
|
Dec 01
2025
|
Sukumar Nagendran President and Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
260,047
+17.04%
|
$260,047
$1.71 P/Share
|
|
Nov 28
2025
|
Sukumar Nagendran President and Head of R&D |
SELL
Open market or private sale
|
Direct |
110,125
-9.86%
|
$440,500
$4.75 P/Share
|
|
Nov 28
2025
|
Sukumar Nagendran President and Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
110,125
+4.79%
|
$110,125
$1.21 P/Share
|
|
Sep 10
2025
|
Sukumar Nagendran President and Head of R&D |
SELL
Open market or private sale
|
Direct |
200,000
-16.58%
|
$600,000
$3.23 P/Share
|
|
Sep 10
2025
|
Sukumar Nagendran President and Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
41,150
+3.3%
|
$0
$0.7 P/Share
|
|
Aug 21
2025
|
Kamran Alam CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
54,491
-4.39%
|
$108,982
$2.85 P/Share
|
|
Aug 21
2025
|
Sukumar Nagendran President and Head of R&D |
SELL
Open market or private sale
|
Direct |
57,054
-4.67%
|
$114,108
$2.85 P/Share
|
|
Jun 02
2025
|
Laura Sepp Lorenzino |
BUY
Grant, award, or other acquisition
|
Direct |
56,623
+34.85%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 750K shares |
|---|---|
| Grant, award, or other acquisition | 2.02M shares |
| Exercise of conversion of derivative security | 611K shares |
| Payment of exercise price or tax liability | 29.8K shares |
|---|---|
| Open market or private sale | 1.28M shares |